FDA Approves Celgene’s Azacitidine for Juvenile Leukemia

FDA approves Bristol-Myers Squibb division Celgene’s Vidaza (azacitidine) for pediatric patients with newly diagnosed juvenile myelomonocytic leukemia.

NOTE

• Bristol-Myers Squibb Co. shares were little changed in postmarket trading as of 4:01 p.m. New York time
  • The average 12-month price target of $78.63 is 3.2% above the current price
  • 14 buys, 6 holds, 2 sells

To view the source of this information, click here

To contact the reporter on this story:
Jim Silver in New York at jsilver@bloomberg.net

To contact the editor responsible for this story:
Sunil Kesur at skesur@bloomberg.net

© 2022 Bloomberg L.P. All rights reserved. Used with permission.